119 related articles for article (PubMed ID: 19738391)
1. Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy.
Argyriou AA; Antonacopoulou AG; Scopa CD; Kottorou A; Kominea A; Peroukides S; Kalofonos HP
Oncology; 2009; 77(3-4):254-6. PubMed ID: 19738391
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity.
Basso M; Modoni A; Spada D; Cassano A; Schinzari G; Lo Monaco M; Quaranta D; Tonali PA; Barone C
Cancer Chemother Pharmacol; 2011 May; 67(5):1179-87. PubMed ID: 20872144
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
[TBL] [Abstract][Full Text] [Related]
4. A review on oxaliplatin-induced peripheral nerve damage.
Argyriou AA; Polychronopoulos P; Iconomou G; Chroni E; Kalofonos HP
Cancer Treat Rev; 2008 Jun; 34(4):368-77. PubMed ID: 18281158
[TBL] [Abstract][Full Text] [Related]
5. Peripheral neuropathy induced by oxaliplatin-based chemotherapy.
J Support Oncol; 2006 Feb; 4(2):82-3. PubMed ID: 16499128
[No Abstract] [Full Text] [Related]
6. Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy?
Antonacopoulou AG; Argyriou AA; Scopa CD; Kottorou A; Kominea A; Peroukides S; Kalofonos HP
Eur J Neurol; 2010 Jul; 17(7):963-8. PubMed ID: 20192979
[TBL] [Abstract][Full Text] [Related]
7. Pain in oxaliplatin-induced neuropathy--sensitisation in the peripheral and central nociceptive system.
Binder A; Stengel M; Maag R; Wasner G; Schoch R; Moosig F; Schommer B; Baron R
Eur J Cancer; 2007 Dec; 43(18):2658-63. PubMed ID: 17855072
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy.
Kautio AL; Haanpää M; Kautiainen H; Leminen A; Kalso E; Saarto T
Anticancer Res; 2011 Oct; 31(10):3493-6. PubMed ID: 21965767
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy.
Argyriou AA; Chroni E; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP
Neurology; 2006 Dec; 67(12):2253-5. PubMed ID: 17190958
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy.
Sereno M; Gutiérrez-Gutiérrez G; Rubio JM; Apellániz-Ruiz M; Sánchez-Barroso L; Casado E; Falagan S; López-Gómez M; Merino M; Gómez-Raposo C; Rodriguez-Salas N; Tébar FZ; Rodríguez-Antona C
BMC Cancer; 2017 Jan; 17(1):63. PubMed ID: 28103821
[TBL] [Abstract][Full Text] [Related]
11. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin.
Tofthagen C; McAllister RD; McMillan SC
Clin J Oncol Nurs; 2011 Apr; 15(2):182-8. PubMed ID: 21444285
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.
Lehky TJ; Leonard GD; Wilson RH; Grem JL; Floeter MK
Muscle Nerve; 2004 Mar; 29(3):387-92. PubMed ID: 14981738
[TBL] [Abstract][Full Text] [Related]
13. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
[TBL] [Abstract][Full Text] [Related]
14. [Roles of TRPA1 in acute peripheral neuropathy characteristically induced by oxaliplatin].
Nakagawa T; Zhao M; Shirakawa H; Kaneko S
Nihon Yakurigaku Zasshi; 2013 Feb; 141(2):76-80. PubMed ID: 23391546
[No Abstract] [Full Text] [Related]
15. Failure to find evidence for association between voltage-gated sodium channel gene SCN2A variants and febrile seizures in humans.
Nakayama J; Yamamoto N; Hamano K; Iwasaki N; Ohta M; Nakahara S; Horigome Y; Nakahara C; Noguchi E; Shiono J; Shimakura Y; Yamakawa-Kobayashi K; Matsui A; Arinami T
Neurosci Lett; 2002 Aug; 329(2):249-51. PubMed ID: 12165424
[TBL] [Abstract][Full Text] [Related]
16. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
Argyriou AA; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP; Chroni E
Acta Oncol; 2007; 46(8):1131-7. PubMed ID: 17851880
[TBL] [Abstract][Full Text] [Related]
17. Persistent neuropathy after treatment with cisplatin and oxaliplatin.
Brouwers EE; Huitema AD; Boogerd W; Beijnen JH; Schellens JH
Acta Oncol; 2009; 48(6):832-41. PubMed ID: 19308757
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced peripheral neuropathy: A need for standardization in measurement.
Dunlap B; Paice JA
J Support Oncol; 2006 Sep; 4(8):398-9. PubMed ID: 17004514
[No Abstract] [Full Text] [Related]
20. [Genetic backgrounds of peripheral neuropathy induced by oxaliplatin].
Mitsuma A; Ando Y
Nihon Yakurigaku Zasshi; 2013 Feb; 141(2):62-5. PubMed ID: 23391543
[No Abstract] [Full Text] [Related]
[Next] [New Search]
